Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Change in Cash: 2014-2024

Historic Change in Cash for Rocket Pharmaceuticals (RCKT) over the last 11 years, with Dec 2024 value amounting to $107.7 million.

  • Rocket Pharmaceuticals' Change in Cash rose 59.78% to $43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 106.47%. This contributed to the annual value of $107.7 million for FY2024, which is 227.36% up from last year.
  • Rocket Pharmaceuticals' Change in Cash amounted to $107.7 million in FY2024, which was up 227.36% from -$84.6 million recorded in FY2023.
  • Rocket Pharmaceuticals' Change in Cash's 5-year high stood at $111.8 million during FY2020, with a 5-year trough of -$92.2 million in FY2022.
  • For the 3-year period, Rocket Pharmaceuticals' Change in Cash averaged around -$23.0 million, with its median value being -$84.6 million (2023).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Change in Cash crashed by 157.83% in 2021, and later spiked by 227.36% in 2024.
  • Yearly analysis of 5 years shows Rocket Pharmaceuticals' Change in Cash stood at $111.8 million in 2020, then plummeted by 157.83% to -$64.6 million in 2021, then plummeted by 42.63% to -$92.2 million in 2022, then climbed by 8.24% to -$84.6 million in 2023, then spiked by 227.36% to $107.7 million in 2024.